New Mechanism of Action Data for NT219 Presented at Epigenetics and Metabolism AACR Special Virtual Conference
16 oct. 2020 07h21 HE
|
Kitov Pharma Ltd.
Data Further Support Potential of NT219 to Overcome Cancer Drug Resistance TEL AVIV, Israel, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage...
Kitov Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients
08 sept. 2020 07h10 HE
|
Kitov Pharma Ltd.
TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Pharma Receives Notice of Intention to Grant Two Patents in China Covering Company’s Lead Oncology Assets, CM24 and NT219
04 sept. 2020 08h00 HE
|
Kitov Pharma Ltd.
Kitov’s patent coverage for CM24 and NT219 now extends to the U.S., EU, China, and multiple ROW countries TEL AVIV, Israel, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”)...
Kitov Pharma Announces ADS Ratio Change
12 août 2020 16h55 HE
|
Kitov Pharma Ltd.
TEL AVIV, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Pharma Provides Corporate Update and Reports First Half 2020 Financial Results
11 août 2020 07h15 HE
|
Kitov Pharma Ltd.
TEL AVIV, Israel, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Announces Initiation of Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients
09 juil. 2020 07h30 HE
|
Kitov Pharma Ltd.
Company Evaluating NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for the Treatment of Recurrent and/or Metastatic Solid Tumors and Head and Neck Cancer ...
Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody
08 juil. 2020 07h30 HE
|
Kitov Pharma Ltd.
Patent coverage for CM24 now extends to the U.S. and the EU TEL AVIV, Israel, July 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company...
Kitov Pharma Issues CEO Shareholder Letter Providing Business Update
02 juil. 2020 08h34 HE
|
Kitov Pharma Ltd.
• Emerging oncology pipeline continues to advance• Strong balance sheet with over $60M in cash TEL AVIV, July 02, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE:...
Kitov Closes $35.0 Million Registered Direct Offering
25 juin 2020 16h30 HE
|
Kitov Pharma Ltd.
TEL-AVIV, Israel, June 25, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Announces $35.0 Million Registered Direct Offering
23 juin 2020 13h20 HE
|
Kitov Pharma Ltd.
TEL-AVIV, Israel, June 23, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...